World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
46824
World Ranking
11091
National Ranking
5707

Overview

Justin F. Gainor is affiliated with Harvard University in the United States and specializes in medicine, with a focus on oncology and pulmonary and respiratory medicine. Their research portfolio includes significant contributions to cancer research, molecular biology, immunology, and related fields.

Gainor's recent publications reflect their involvement in lung cancer treatment and research. Notable papers include:

  • Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study, 2021, The Lancet Oncology
  • Lung cancer, 2021, The Lancet
  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation, 2021, Cancer Discovery

These publications cover clinical trials and molecular mechanisms pertinent to lung cancer, targeting specific genetic mutations and therapeutic resistance.

The frequent coauthors collaborating with Gainor include:

  • W. Marston Linehan
  • Mark M. Awad
  • Subba R. Digumarthy
  • Mari Mino-Kenudson
  • Vivek Subbiah

Gainor's work has been predominantly published in high-impact and specialized venues such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts

The scientist's research is substantially grounded in the field of medicine, with 516 publications. Subfields include oncology with 231 publications, pulmonary and respiratory medicine with 184, molecular biology with 46, immunology with 35, and cancer research with 32. Specific topics frequently addressed in their studies are:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research

This profile reflects Gainor's focused efforts on lung cancer research, particularly on targeted therapies and immunotherapy, aligning with evolving priorities in oncology and precision medicine.

Best Publications

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

  • The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

    Luc Friboulet;Nanxin Li;Ryohei Katayama;Christian C. Lee

  • Patient-derived models of acquired resistance can identify effective drug combinations for cancer

    Adam S. Crystal;Alice T. Shaw;Lecia V. Sequist;Luc Friboulet

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

    Alice T Shaw;Enriqueta Felip;Todd M Bauer;Benjamin Besse;Benjamin Besse

  • ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

    Catherine A Shu;Justin F Gainor;Mark M Awad;Codruta Chiuzan

  • Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F.

    Shaw At;Friboulet L;Leshchiner I;Gainor Jf

  • PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

    Helen Y. Zou;Luc Friboulet;David P. Kodack;Lars D. Engstrom

  • Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

    L. V. Sequist;R. S. Heist;A. T. Shaw;P. Fidias

  • Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

    Everett E. Vokes;N. Ready;E. Felip;L. Horn

  • Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

    Mark M. Awad;Ryohei Katayama;Michele McTigue;Wei Liu

  • Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer

    J. Gainor;L. Dardaei;S. Yoda;L. Friboulet

Frequent Co-Authors

Alice T. Shaw
Alice T. Shaw Harvard University
Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Mark M. Awad
Mark M. Awad Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Beow Y. Yeap
Beow Y. Yeap Harvard University
A. John Iafrate
A. John Iafrate Harvard University
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA isn’t the only route to a health-focused career. Many online programs now offer flexible, accredited pathways in related fields, making advanced education more accessible to busy professionals and career changers.

For nurses aiming to advance, rn to np bridge programs provide a seamless way to move from an associate’s degree to a nurse practitioner role—all while working. Those interested in nutrition and wellness can earn an online dietitian degree, which prepares graduates for careers as registered dietitians or nutritionists.

Healthcare administrators can benefit from cahme accredited mha online programs, which are widely recognized and can unlock leadership opportunities in hospitals and clinics. Meanwhile, nurses looking to advance with minimal interruptions can consider rn to bsn no clinical hours programs, ideal for those balancing work and study.

Exploring these online options helps broaden career possibilities beyond traditional medical school, providing flexible and respected alternatives for aspiring healthcare professionals.

Best Scientists Citing Justin F. Gainor

Trending Scientists